论文部分内容阅读
目的观察尿激酶(UK)静脉溶栓治疗急性心肌梗死的疗效。方法选择急诊急性心肌梗死患者132例,随机分为治疗组68例和对照组64例,治疗组给尿激酶溶栓治疗,而对照组给予常规治疗。用药后观察两组患者血管再通情况和病死率以及并发症发生情况。结果治疗组总的血管再通率高于对照组(P<0.01);治疗4周后,对照组的病死率、急性肺水肿和心源性休克发生率高于治疗组(P<0.01)。结论尿激酶静脉溶栓疗效可靠、安全、使用方便、不良反应发生率低且轻微,适合基层医院对AMI的抢救。
Objective To observe the curative effect of urokinase (UK) intravenous thrombolysis on acute myocardial infarction. Methods 132 patients with acute myocardial infarction were randomly divided into treatment group (n = 68) and control group (n = 64). The treatment group received urokinase thrombolytic therapy while the control group received conventional treatment. After treatment, the vascular recanalization and case fatality rate as well as the complication of the two groups were observed. Results The total recanalization rate of the treatment group was higher than that of the control group (P <0.01). After 4 weeks of treatment, the mortality, acute pulmonary edema and cardiogenic shock in the control group were higher than those in the control group (P <0.01). Conclusion The urokinase thrombolytic therapy is reliable, safe, easy to use and the incidence of adverse reactions is low and mild, which is suitable for the rescue of AMI in primary hospitals.